December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

14.67 +3.38 (+29.92%)
Streaming Delayed Price Updated: 10:46 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder. 
Via Stocktwits
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
MoonLake Therapeutics Stock Sparks Retail Frenzy Ahead Of New York Summit — Traders See 'Nonstop Catalysts' Through 2026 ↗
Via Stocktwits
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades ↗
Via Stocktwits
MoonLake Immunotherapeutics Stock Draws Buzz After Skin Drug’s Phase 3 Trial Data — Retail Speculates Buyout, Bigger Gains ↗
Via Stocktwits
News headline image
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting. 
Via The Motley Fool
Topics Lawsuit Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
The Best AI for Picking Stocks, Ranked by Performance ↗
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Which stocks have an unusual volume on Monday? ↗
Volume analysis on 2025-10-06: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 ↗
 
Via Benzinga
News headline image
Unusual volume stocks are being observed in Friday's session. ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
Unusual volume stocks are being observed in Thursday's session. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside ↗
Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares. 
Via Stocktwits
News headline image
Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down ↗
U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by... 
Via Chartmill
Topics Cannabis
News headline image
Wolfspeed, Tilray, Robinhood, Etsy, And Moonlake Immunotherapeutics: Why These 5 Stocks Are On Investors' Radars Today ↗
U.S. stocks advanced today, with the Nasdaq climbing about 107 points, or 0.48%, to 22,591.15. The S&P 500 added 0.26% to close at 6,661.21, while the Dow Jones Industrial Average edged up 0.15% to... 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.... 
Via Benzinga
News headline image
Nasdaq Jumps 150 Points; US Pending Home Sales Rise ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
News headline image
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment ↗
MoonLake Immunotherapeutics stock crashed Monday after the company posted mixed results for its skin disease drug. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million. 
Via Benzinga
News headline image
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1... 
Via Benzinga
Topics Stocks
News headline image
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Why Is MoonLake Immunotherapeutics Stock Crashing Premarket? ↗
RBC Capital downgraded the stock, calling the results a “near-miss” statistically and warning that the drug’s effect size looked uncompetitive. 
Via Stocktwits
News headline image
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its... 
Via Benzinga
News headline image
2 Small-Cap Biotech Stocks Well Positioned for a Breakout ↗
Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof. 
Via The Motley Fool
News headline image
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery ↗
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial. 
Via Benzinga
News headline image
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.